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The Problem
In considering the development of a new
vaccine, preventive immunization, generally
considered the most cost-effective health
intervention, should be ranked against other
strategies for disease control, such as case
management (treatment of disease) or control of
environmental factors linked to vector preva-
lence and dynamics (e.g., overpopulation, rural-
to-urban migration, economic status, vector
control, inadequate domestic water supply or
sewage disposal) (1). Evaluating vaccination
options and economic impact is particularly
important for vaccines against low-prevalence or
geographically contained emerging infectious
diseases with limited demand, for which
development costs may not be recovered. Thus,
consensus should be reached on the mid- to long-
term public health significance (e.g., vector
dynamics and potential control, age prevalence
and targets, risk categories, case-fatality rates,
and possible future epidemiologic scenarios) of
any vaccine-preventable disease. Without clear
premises and long-term commitment, the
development of vaccines for rare infectious
diseases or those of narrow scope (e.g.,
geographically limited but regionally important
diseases such as arboviral or diarrheal diseases)
or for which development costs offset the market
potential, called here orphan vaccines, may be
considered a precarious venture that most
organizations would hesitate to pursue.
Disincentives for Orphan Vaccine
Development
Competing Costs
Vaccine development involves a substantial
investment in time, effort, and resources. Any
private- or public-sector vaccine research and
development process involves choices concerning
the allocation of resources at all levels, including
personnel and management. The costs from
research to licensure, the risks inherent in
vaccine development (e.g., technological con-
straints, regulatory approval) and the short- and
long-term market financial evaluations (e.g., net
present value, return on investment [2]) are key
factors in the decision to develop a vaccine
against a rare disease. In addition, long-term
market evaluation and return on investment are
often difficult to estimate because of the
Development of Orphan Vaccines:
An Industry Perspective
Jean Lang and Susan C. Wood Jean Lang and Susan C. Wood Jean Lang and Susan C. Wood Jean Lang and Susan C. Wood Jean Lang and Susan C. Wood
Pasteur Mérieux Connaught, Lyon, France
Address for correspondence: Jean Lang, Vector-Borne
Diseases Clinical Program, R&D Clinical Development
Department, Pasteur Mérieux Connaught, Lyon, France; fax:
33-47-273-7928; e-mail: jlang@fr.pmc-vacc.com.
The development of vaccines against rare emerging infectious diseases is
hampered by many disincentives. In the face of growing in-house expenditures
associated with research and development projects in a complex legal and regulatory
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their product portfolio. Nevertheless, for humanitarian reasons, there is a need to
develop niche vaccines for rare diseases not preventable or curable by other means.
The U.S. Orphan Drug Act of 1983 and a similar proposal from the European
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leadership; and the long-term pharmacoeconomic viability of orphan products will be key
factors in overcoming the complexity of orphan status and the limited need for vaccine.750 750 750 750 750 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
Perspectives Perspectives Perspectives Perspectives Perspectives
unpredictable nature of disease outbreaks and
vector dynamics. Growing in-house expendi-
tures associated with research and development
projects in a complex legal and regulatory
environment prompt most pharmaceutical
companies to prioritize their projects and
streamline their product portfolio (3). The same
is true in the public health sector where the
appearance of an orphan vaccine would increase
the already tough competition for resources, as
evidenced by the present shortcomings in
developing countries’ use of current and
candidate Expanded Program of Immunization
(EPI) vaccines (hepatitis B, measles, yellow
fever,  Haemophilus influenzae type b).
Vaccine Pricing
It has been repeatedly shown that one of the
most accurate predictors of the successful use of
an EPI vaccine, such as hepatitis B, is not
necessarily the endemicity of the disease but
instead the vaccine cost per dose (4,5). Thus, the
research, development, production, marketing,
and distribution of a safe and effective vaccine
should be assessed to determine if its potential
cost per dose would be acceptable in an already
difficult marketplace (4). The limited economic
prospects and size of the market, with probably
no prospect for economies of scale in production,
are particularly relevant in the vaccine industry.
Economic models of vaccine production have
shown an inverse relationship between the
number of doses produced and the cost per
dose (6). As a consequence, a tiered pricing
strategy has been endorsed by the World Health
Organization (WHO), in which high-cost but low-
volume vaccine sales in industrialized countries
could subsidize the low cost and larger volume of
sales in developing countries, although this may
not be feasible if the quantity of vaccines needed
in developing countries is low (6,7).
Patent Protection and Product Liability
Introduction of new vaccines relies heavily
on the strategic use of intellectual property
rights to reassure investors that a candidate
vaccine will provide a fair return on invested
funds. The lack of patent protection or legal
framework for intellectual property rights in
some developing countries interferes with the
long-term viability of a vaccine. In Western
countries, liability issues associated with a
candidate vaccine and its intended population (8)
also affect development costs.
Orphan Drugs and Vaccines Situation in
the United States
The United States was the first nation to
propose a legal framework to overcome the
disincentives to developing orphan drugs and
encourage their development and availability
(9,10). The Preamble on Orphan Drugs to the
legislation passed by the U.S. Congress
contained the following points: 1) Many diseases
and conditions (so-called orphan diseases) exist
that affect very small numbers of persons;
however, the overall group of patients affected by
such diseases totals 20 million or more in the
United States; 2) adequate drugs for orphan
diseases have not been developed; 3) pharmaceu-
tical companies may reasonably expect to
generate relatively small sales in comparison to
the cost of developing an orphan product; and 4)
costs of developing such drugs should be reduced,
and financial incentives should be provided.
The legislation defines two classes of orphan
diseases. The first class comprises diseases that
affect fewer than 200,000 Americans. In this
case, sales of a drug, vaccine, diagnostic test, or
blood product intended for use in such a disorder
would be insufficient to offset the costs incurred
during development and marketing of the
product. This program is directed at public
health needs beyond the U.S. borders, providing
a stimulating factor for the U.S. pharmaceutical
community to develop products to meet the needs
of populations elsewhere. The second class of
orphan diseases affects more than 200,000
Americans but has no potential recovery costs
from U.S. sales. Thus, the program may also
apply to specific subpopulations of patients with
a more common disease for which the sponsor
does not expect to offset development and
marketing costs in the first 7 years of sales.
Concerning vaccines, the U.S. Food and
Drug Administration (FDA) stipulated that,
when establishing the claim for orphan status,
the intended population should reflect the
number of persons who would receive the vaccine
annually as of the date of designation.
Orphan Drug Incentives
To further encourage orphan drug availabil-
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for orphan drug development were issued by the
Office of Orphan Products Development, under
the auspices of FDA (11). The sponsor makes the
request for orphan drug status (before filing a
New Drug Application or a Product License
Application) on the basis of information and
circumstances at the time the request is submitted.
Funds for research through Orphan Prod-
ucts Grants Programs benefit from a 50%
deduction tax credit for clinical trial expenses (9)
and a market exclusivity of 7 years. Protocol
assistance in the form of written recommenda-
tions from the secretary of the Department of
Health and Human Services for the nonclinical
and clinical investigations needed for marketing
approval are provided to accelerate the approval
process. In this respect, a flexible approach has
been adopted for the development of orphan
drugs. For example, the preclinical dossier (i.e.,
the pharmaceutical and pharmacotoxologic data
included in the registration file) may not have to
include data on animal toxicity, and teratogenic-
ity or carcinogenicity results may be waived in
some cases (12). This flexibility in the
registration requirements can be applied in
certain cases to expedite the approval process
but cannot be used in instances where it could
compromise the safety of the consumer.
The legislation states that the clinical dossier
of an orphan drug or vaccine should be built on a
realistic assessment of the qualitative and
quantitative nature of the studies that can be
performed. This measure is relevant because the
orphan nature of the disease and its prevalence
in regions with limited medical facilities and
services may make it difficult to recruit a large
enough number of qualified participants for a
clinical trial. On the other hand, the drawback of
basing a clinical dossier on a limited amount of
data is the obvious difficulty in evaluating the
safety profile of an orphan product with
sufficient statistical confidence. On average,
orphan drugs may be associated with greater
hazard than other products. For example, during
clinical testing, 31% of orphan drugs on the
market had more pronounced adverse effects
than nonorphan medicinal products (13). Likewise,
after FDA approval, 13% of orphan products
provoked more side effects than anticipated.
To encourage development of novel orphan
compounds, FDA stipulated that two products
would be considered the same (and thus the
latter one would not qualify for the incentives in
the Orphan Drug Act), unless the second product
was shown to be clinically superior to the first.
This stipulation provides a clear incentive for the
original manufacturer of a product likely to be
reproduced, who funds the full costs of research
and development. For example, in the case of two
live, attenuated viral vaccines, only the first
would be granted orphan status for a given
preventive indication, unless the second vaccine
proved clinically superior.
Liability Coverage
Although not definitely clarified, proposals
have been made to solve some specific liability
issues, including design defects, duty to warn,
negligence in testing or manufacturing, and
defining responsibility for no-fault injury (13).
The National Vaccine Compensation Program
(issued in 1986), which provides no-fault
compensation for vaccine-related injuries, is
financed by a trust fund created by an excise tax
on every dose of vaccine sold (14).
Orphan Drugs and Vaccines in Europe
In 1994, the European Commission (the
legislative body of the European Union [EU])
stated its interest in orphan diseases. In 1998,
with close collaboration of the French Ministry of
Health (15) and the European Medicine
Evaluation Agency, a text was approved
recommending the creation of a European Office
for Orphan Drugs along the same lines as the
U.S. Office of Orphan Products Development.
The proposed European criteria for classifi-
cation of a drug as an orphan drug (including
vaccines) are almost identical to the U.S. criteria,
except that they are based on a disease
prevalence of 5 per 10,000 Europeans (falling
between the United States [7 per 10,000] and
Japan [2.5 per 10,000]), when no current methods
of diagnosis, prevention or treatment, or major
contribution to current patient care exist.
The legislation will provide incentives to the
European pharmaceutical industry in terms of
research and development assistance (protocol
assistance, normal evaluation, possible form of
centralized but fast-track approval procedures),
fee waiver, tax credits, funds from the European
Orphan Product Grant Program, and market
exclusivity for 10 years (interim period 6 years)
and will encourage national policies (subsidiary752 752 752 752 752 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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principle, e.g., the French compassionate use
authorization [Autorisation Temporaire
Utilisation]) (16).
The role of patient groups in increasing
awareness of orphan drug development has been
widely recognized for pharmaceutical orphan
drugs in the United States and has been
emphasized in the European project. The
potential end-users of an orphan product may
not be aware of therapeutic or preventive
options. The European Office of Orphan
Products Development will therefore support the
establishment of groups of persons with the same
rare conditions to play a role in increasing
awareness of the disease within the population
and will coordinate their activities at national
and community levels. It remains to be seen how
this initiative will apply to vaccine-preventable
infectious diseases in communities where
individuals or groups may not be aware of the risk
for infection and thus the value of the vaccine.
To clarify the extent of patent protection and
the right to benefit from the orphan incentive
package, the European Commission (DG24
committee) recently defined “similarity” between
orphan products as the same substance, or a
substance that differs from the original substance
in molecular structure, source material, or
manufacturing process, or an organism (living or
nonliving) that is comparable with the original
substance or organism in terms of biologic action
and properties (including efficacy and safety)
and ability to act through the same mechanism.
In the same way as the U.S. legislation, this
would favor the development of novel orphan
products by the innovative company.
In June 1999, the European Parliament’s
committee on the environment, public health,
and consumer protection adopted a report by one
of its senior members in favor of the Policy on
Orphan Drugs and proposed some amendments
to widen the scope of the legislation. Among
other changes, the committee requested more
flexibility in the proposed provisions for clinical
trials, allowing (under specific conditions)
availability of the product before final authoriza-
tion is granted. The committee proposed
extending the definition of orphan drug status to
cover products intended for serious and chronic
diseases. It also recommended, as in the United
States, additional incentives for developing
medicinal or biologic products for diseases that
occur mainly in tropical regions but rarely
within EU territory. Finally, the committee
called for an Orphan Medicinal Product Innovation
Promotion Fund to be financed from the sales of
orphan drugs after the proposed 10-year period
of market exclusivity. The European Orphan Drug
Policy could be enacted early in the year 2000.
Orphan Drugs in Other Industrialized
Countries
After the U.S. Orphan Drug Act, similar
legislation was enacted in Japan in 1993. An
Australian orphan drugs program based on the
U.S. program began in 1998 (17). Since then, the
Therapeutic Goods Administration has designated
two biological drugs as orphans—rabies immuno-
globulin and recombinant enzyme imiglucerase for
replacement therapy in patients with Gaucher
disease. A cross-national comparison of orphan
drug and vaccine policies has been made for
different countries, including Japan, Canada,
France, Sweden, and the United Kingdom (12).
Orphan Vaccines in Developing Countries
The availability and use of orphan vaccines
in developing countries are complex since these
countries have yet to ensure optimum use of
existing priority vaccines (17). The limitations
and obstacles involved in expanding the use of
these priority vaccines are further multiplied for
orphan vaccines of limited need. Within the
framework of WHO, the Children’s Vaccine
Initiative         set the development of vaccines with
commercial prospects as a priority measure (7).
This cost-oriented definition reflects mainly the
difficulty of developing vaccines and drugs for
tropical diseases, even those as prevalent as
malaria (19,20). The Children’s Vaccine
Initiative’s role has been problematic for various
reasons (21), and this structure has faced
increasing difficulties in maintaining its visibility.
Nevertheless, other noneconomic factors (3)
could justify an industry’s decision to develop
and market an orphan vaccine: desire to enhance
the company’s ethical profile by fulfilling a
medical or social need; capacity to develop,
produce, and market the drug; a larger company
strategy (e.g., part of a product range); and
possible additional uses that would increase the
drug’s future economic viability. The latter point
may be less relevant for vaccines, which are
usually tailor-made to their infectious agents.
In the development of any vaccine against an
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rules apply (4,6,18,22), for example, developing
strong research and development capacity,
obtaining reliable scientific results and training
in industrialized and developing countries; bulk
filling arrangements; licensing technology;
negotiating partnerships for specific products;
joint venture agreements with western research
and development manufacturers (economic
value of the alliance); identifying the neediest
countries on the basis of a banding strategy that
classes countries according to their gross
national product per capita, thereby allowing
tiered pricing among them (6,23); and creation of
funding mechanisms. Some could argue that
from an industry perspective, if all of these
criteria cannot be met, the vaccine should not be
developed.
No trade-off on the quality of an orphan
vaccine is ethically justified or accepted. For the
pharmaceutical industry, therefore, the costs
incurred in development, ensuring tight quality
controls, and establishing industrial good
manufacturing procedures for an orphan vaccine
are similar to those incurred with a traditional
vaccine. For this reason, the development of any
orphan vaccine should be broadly supported by
measures to increase the awareness of immuni-
zation benefits at three levels—the decision-
makers, the caregivers, and the patients.
Increasing Orphan Vaccine Availability
Development of orphan vaccines is guided by
the limited need for or market potential of the
product, with the accompanying regulations, as
well as the specific characteristics of the vaccine
and those who need it (24). Because of the pitfalls
related to these limitations, few orphan vaccines
have reached the neediest populations. For
example, in the United States, by the end of
1997, 837 medicinal products had been
designated orphan drugs; 152 of these obtained
authorization. This number was a clear
improvement over that of the previous 14 years,
during which 34 medicinal orphan products
obtained authorization. However, our website
review found only eight vaccines registered with
orphan status (seven for therapeutic indications
[e.g., cancer and sickle cell anemia], one to
prevent an Asiatic infectious disease—Japanese
encephalitis virus) and, to our knowledge, none
has yet obtained final authorization. In addition,
“It is not vaccines that save lives but
vaccination.” Even when orphan vaccines are
available, we have to examine the feasibility of
getting them to the intended population.
Various strategies, proposals, and recom-
mendations for overcoming limitations inherent
in orphan vaccine development and availability
are listed in the Table.
Providing Information, Prioritizing, and
Securing Demand
Although funding is a major obstacle to
orphan vaccine development, it may not be the
only impediment to the introduction of new
vaccines (25). Reliable information on the
epidemiology, disease severity, and effect on
public health is essential to substantiating the
need for a vaccine and may not be available to
support the development decision. Market forces
may not always be good cultivators of vaccines,
which, unlike some chemical drugs, are not big
money-making products. For this reason, the
public and decision makers should know about
the benefits of immunization, to increase disease
awareness, and support an orphan vaccine
initiative.
Facilitating Vaccine Research and
Development and National and Regional
Approvals
An accelerated procedure for final authoriza-
tion and exemptions from all or part of the
registration fee can reduce development costs,
staffing requirements, and time to market and
render the development of an orphan vaccine
more attractive for the sponsor. Local initiatives
may also speed the authorization process.
Ensuring Market and Funding Visibility,
Production, and Distribution
Finally, increasing patent protection and the
defined period of market exclusivity reduces
investment risks for manufacturers. Further-
more, funding for orphan projects may be
advanced from private bodies looking to
capitalize on an ethical business image. Indeed,
the private sector looks to take on an
increasingly important role in international
health development, especially in poorer
countries (26). Increased world travel and the
risk for transport of pathogens across borders
(27) support tiered pricing between the western
traveler and the disease-endemic country. In
addition, an orphan infectious agent in a remote
developing country requiring an orphan vaccine754 754 754 754 754 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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Table. Solutions and proposals for accelerating orphan vaccine availability
1. Provide information, prioritize, and secure demand
Increase awareness of disease: set-up of special interest groups (patients, parents, professionals), expert
groups, and national forums.
Acquire epidemiologic data on selected infectious diseases to guide decision-making: obtain access to data
registries with comparable case-definitions across countries, and obtain information from specialized
units and experts, scientific literature, patient organizations,and pharmaceutical manufacturers
associations.
Establish the suitability of vaccine prevention vs. other options: realistic comparisons of vaccination with
patterns and costs of other alternatives, such as treatment or vector control.
 Ensure political support for orphan vaccine initiatives and organize tripartite partnerships between
public, private, and nongovernmental sectors.
2. Facilitate vaccine research and development and national/regional approvals
Promote innovative research and development technologies that could be applied to blockbuster vaccines
or, alternatively, promote low-cost traditional vaccine technologies.
Encourage public/private sector links: academic/industrial research groups.
Set international standards of quality, safety, and efficacy and define minimum amount of data required
for licensure.
Make recommendations on appropriate schedules, target ages.
Promote national and regional ex-U.S. and European Community incentives on Orphan Drug Policies
(Latin America, Asia).
Expand and harmonize orphan drug policies as part of the ICH process (decrease time to regulatory
approval).
3. Ensure market/funding visibility, production and distribution
Reduce investment risks for manufacturers by providing realistic demand estimates.
Fund development of orphan vaccines for developing countries through various institutional bodies, such
as CVI, WHO, UNICEF, PAHO, WB, USAID, NIH, CDC, PATH, other donor bodies, and nongovern-
mental organizations and foundations (e.g., Gates Foundation) on the basis of target assistance for the
neediest countries based on total gross national product.
Strengthen political and public health collaboration between orphan programs (European Community,
United States) and other countries to create a supranational office dedicated to orphan vaccines
(World Office of Orphan Vaccine Development or CVI) that could harmonize and coordinate funding
(from research to manufacturing) from various sources.
Identify and expand the pool of the committed purchasers based on expected coverage criteria.
Promote and support protection of intellectual property.
Clarify compensation programs that may assume responsibility for liability.
Evaluate tiered pricing (high/low) feasibility at two levels:
 Multinational: traveler or military vaccines in industrialized countries, endemic community vaccines in
developing countries.
 National: a private market for the high GNP per capita subgroup, a public market for the low GNP per
capita subgroup.
Establish manufacturing strategies, such as campaigning to subsidize orphan vaccine cost investments by
large volume sales of EPI vaccines.
Strengthen the vaccine distribution network for the targeted population.
ICH, International Conference on Harmonization; CVI, Children’s Vaccine Initiative; WHO, World Health Organization;
UNICEF, United Nation’s Children’s Fund; PAHO, PanAmerican Health Organization; WB, World Bank; USAID, U.S. Agency
for International Development; NIH, National Institutes of Health; CDC, Centers for Disease Control and Prevention; PATH,
Program for Appropriate Technology in Health; EPI, Expanded Program of Immunization.
with limited need could, over time, become an
emerging disease worldwide. HIV is a case in
point: a disease originating in Africa that has
successfully spread to the industrialized world.
In Argentina, strong political and govern-
mental support, aided by the U.S. Army Medical
Research Institute of Infectious Diseases
collaboration, ultimately culminated in a
successful Candid 1 vaccination campaign
against Argentinean hemorrhagic fever in
agricultural workers (28). Close collaboration
between the pharmaceutical sector, WHO, and
the Chinese government resulted in the develop-
ment of the antimalarial drug artemisin (29).755 755 755 755 755 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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Conclusions
The dilemmas intrinsic to the development
and distribution of orphan vaccines against
emerging infectious diseases reflect many of the
issues faced by policy makers worldwide with
regards to cost, quality of care, access to care,
and the role of government intervention in
regulating the health-care market (30). In view
of the current globalization of trades and
markets, worldwide orphan vaccine policies and
a specialized organization with a strong
leadership and commitment similar to the
Children’s Vaccine Initiative project for a
National Vaccine Authority may be needed
(6,18). This kind of organization could be
responsible for establishing a list of priority
orphan vaccines and indicating reasons for not
including other vaccines. The organization could
also oversee all stages of vaccine development
and have access to funds that could rapidly be
mobilized. Such a global structure could serve as
a forum for discussing the current limitations on
orphan vaccine development and availability.
Nevertheless, the problems recently faced by the
Children’s Vaccine Initiative indicate the
difficulties in mounting and maintaining such a
worldwide initiative.
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